Ignite Creation Date:
2025-12-25 @ 3:36 AM
Ignite Modification Date:
2026-04-23 @ 12:14 PM
Study NCT ID:
NCT02798705
Status:
RECRUITING
Last Update Posted:
2025-03-14
First Post:
2016-06-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D028227', 'term': 'Amyloid Neuropathies, Familial'}], 'ancestors': [{'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D017772', 'term': 'Amyloid Neuropathies'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D028226', 'term': 'Amyloidosis, Familial'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D000686', 'term': 'Amyloidosis'}, {'id': 'D057165', 'term': 'Proteostasis Deficiencies'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 30}, 'targetDuration': '2 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2016-04-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-03', 'completionDateStruct': {'date': '2030-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-03-12', 'studyFirstSubmitDate': '2016-06-09', 'studyFirstSubmitQcDate': '2016-06-09', 'lastUpdatePostDateStruct': {'date': '2025-03-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-06-14', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2029-04', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'all-cause mortality', 'timeFrame': '2 Years', 'description': 'Comparison of all-cause mortality in amyloidosis patients with or without microvascular disease'}], 'secondaryOutcomes': [{'measure': 'Correlation between IMR and echocardiographic parameters', 'timeFrame': 'within 3 months of diagnosis', 'description': "Correlation between IMR and echocardiographic parameters (E/E', LV ejection fraction, etc.)"}, {'measure': 'Correlation between IMR and serum biochemicalmarkers', 'timeFrame': 'within 3 months of diagnosis', 'description': 'Correlation between IMR and serum biochemicalmarkers (troponin T, NT-proBNP, serum free light chain)'}, {'measure': 'Distribution of CFR or IMR according to pathologic severity of myocardial involvement', 'timeFrame': 'within 3 months of diagnosis', 'description': 'Distribution of CFR or IMR according to pathologic severity of myocardial involvement (Percent amyloid load)'}, {'measure': 'Comparison of CFR or IMR value in amyloidosis patient with or without relative perfusion defect in myocardial perfusion imaging (ex> adenosine-SPECT or perfusion MRI)', 'timeFrame': 'within 3 months of diagnosis'}, {'measure': 'Comparison of CFR or IMR value in different type of amyloidosis (AL type, hereditary type, AA type, senile type)', 'timeFrame': 'within 3 months of diagnosis'}, {'measure': 'Comparison of CFR or IMR value in amyloidosis patient according to current staging by Troponin T, NT-proBNP and free light chain difference', 'timeFrame': 'within 3 months of diagnosis'}, {'measure': 'Optimal cut-off values of physiologic indices (CFR, IMR) for prediction of all-cause mortality', 'timeFrame': '2 Years'}, {'measure': 'Association between physiologic indices and pathologically measured percent area involvement in myocardial interstitium', 'timeFrame': 'within 3 months of diagnosis'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Cardiac amyloidosis', 'Fractional flow reserve', 'Microvascular dysfunction', 'Coronary flow reserve', 'Index of microcirculatory resistance'], 'conditions': ['Cardiac Amyloidosis']}, 'referencesModule': {'references': [{'pmid': '32029139', 'type': 'DERIVED', 'citation': 'Choi KH, Lee JM, Kim SR, Kim D, Choi JO, Kim SJ, Kim K, Kim JS, Koo BK, Jeon ES. Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis. J Am Coll Cardiol. 2020 Feb 11;75(5):560-561. doi: 10.1016/j.jacc.2019.11.045. No abstract available.'}]}, 'descriptionModule': {'briefSummary': 'The aim of the study is to evaluate coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and proportion of overt microvascular disease, defined as depressed CFR as well as elevated IMR in patients with cardiac amyloidosis. The second objective of this study is to compare results of non-invasive test including serum light chain amount, Doppler echocardiography with 2D strain, and cardiac perfusion MRI. The third object of this study is to evaluate the association between physiologic indices and pathologically measured percent area involvement of interstitium.', 'detailedDescription': 'Amyloidosis is rare systemic disorder characterized by the extracellular deposition of misfolded protein in various organ system, including heart. Among the several types of amyloid fibrils, the light chain and transthyretin amyloid proteins most commonly affect the heart.\n\nCardiac amyloid deposits result in increased ventricular wall thickness and produce a restrictive cardiomyopathy presenting primarily as biventricular congestive heart failure. Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis without obstructive epicardial coronary artery disease (CAD). Autopsy studies have shown amyloid deposits around and between cardiac myocytes in the interstitium, the perivascular regions, and the media of intramyocardial coronary vessels. Amyloidosis is thus a prime example of a disorder with the potential to cause coronary microvascular dysfunction via 3 major mechanisms: (1) structural (amyloid deposition in the vessel wall causing wall thickening and luminal stenosis), (2) extravascular (extrinsic compression of the microvasculature from perivascular and interstitial amyloid deposits and decreased diastolic perfusion), and (3) functional (autonomic and endothelial dysfunction).\n\nPrevious basic research presented that adipose arteriole or atrial coronary arterioles showed endothelial dysfunction even after brief exposure to physiologic amounts of light chain, and also showed increased oxidative stress, reduced NO bioavailability, and peroxynitrite production. All these previous evidences imply that coronary microvascular dysfunction and subsequent global ischemic insult can be precursor of overt diastolic or systolic dysfunction in patients with cardiac amyloidosis.\n\nHowever, there have only 1 study which evaluated microvascular function in vivo using N13-ammonium positron emission tomography (PET). In that study, Dorbala et al. demonstrated that amyloidosis patients showed depressed global resting myocardial blood flow (MBF), stress MBF, and CFR and higher minimal coronary vascular resistance, compared with patients with left ventricular hypertrophy. However, low availability, high cost, and limited resolution of N13 ammonium PET precludes the generalizability of the results.\n\nSince thermodilution-derived coronary flow reserve and index or microcirculatory reserve using pressure-temperature wire has been well validated prognostic index in assessment of patients with coronary artery disease or functionally insignificant epicardial coronary stenosis, invasive physiologic assessment might more specifically assess macro- and microvascular function in patients with cardiac amyloidosis. Moreover, adding physiologic measurement in the current frame in diagnosis of cardiac amyloidosis might enhance risk stratification of patients.\n\nTherefore, the current study will perform physiologic assessment including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance in patients with cardiac amyloidosis, and explore correlation among the physiologic indices and conventional measurements of echocardiography, perfusion MRI, serum light chain amount, or NT-proBNP. In addition, the differences of physiologic indices according to disease severity of cardiac amyloidosis, which measured by endomyocardial biopsy findings will be also explored. Since there was no previous study which performed invasive physiologic assessment in amyloidosis patients, this study will be performed as pilot study. Target sample size will be at least 30 patients.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Pathologically confirmed amyloidosis patients with suspected cardiac involvement undergoing coronary angiography for coronary disease evaluation', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subject age 18-85 years old\n* Patients with confirmed cardiac amyloidosis by heart biopsy\n* Patients with confirmed amyloidosis by biopsy other than heart and evidence of cardiac involvement in echocardiography\n* Patients who underwent invasive physiologic assessment within 3 months from diagnosis of primary disease\n\nExclusion Criteria:\n\n* Patients with cardiogenic shock\n* Patients with unstable vital sign that precludes coronary angiography\n* Patients with major bleeding in last 3 months\n* Patients with active bleeding\n* Patients with coagulopathy\n* Patients with severe valvular heart disease\n* Patients who refused to provide informed consent'}, 'identificationModule': {'nctId': 'NCT02798705', 'briefTitle': 'Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis', 'organization': {'class': 'OTHER', 'fullName': 'Samsung Medical Center'}, 'officialTitle': 'Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis: Prospective Registry and Pilot Study', 'orgStudyIdInfo': {'id': 'AMYL2016-04-122'}}, 'contactsLocationsModule': {'locations': [{'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Joo Myung Lee, MD, MPH', 'role': 'CONTACT', 'email': 'drone80@hanmail.net', 'phone': '82-2-3410-1246'}], 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}], 'centralContacts': [{'name': 'Joo Myung Lee, MD, MPH, PhD', 'role': 'CONTACT', 'email': 'drone80@hanmail.net', 'phone': '82-2-3410-1246'}, {'name': 'Ki Hong Choi, MD', 'role': 'CONTACT', 'email': 'cardiokh@gmail.com', 'phone': '82-2-3410-1246'}], 'overallOfficials': [{'name': 'Joo Myung Lee, MD, MPH, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Samsung Medical Center'}, {'name': 'Eun-Seok Jeon, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Samsung Medical Center'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Samsung Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Assistant professor', 'investigatorFullName': 'Joo Myung Lee', 'investigatorAffiliation': 'Samsung Medical Center'}}}}